|
hepatocellular carcinoma |
16 |
|
extracellular vesicles |
11 |
|
nidogen 1 |
11 |
|
pre‐metastatic niche |
11 |
|
tumor necrosis factor receptor 1 |
11 |
|
cervical cancer |
8 |
|
cluster analysis |
8 |
|
dose-dependent effect |
8 |
|
early intervention |
8 |
|
employment |
8 |
|
hallucination |
8 |
|
latent class analysis |
8 |
|
long-term outcomes |
8 |
|
persistent psychotic experience |
8 |
|
schizophrenia |
8 |
|
radiomics |
7 |
|
alcohol drinking |
6 |
|
alcohols |
6 |
|
depressive symptoms |
6 |
|
environment-wide association study |
6 |
|
mental well-being |
6 |
|
moderate drinkers |
6 |
|
physical well-being |
6 |
|
social well-being |
6 |
|
18f-fdg pet |
5 |
|
bioinformatics |
5 |
|
cancer outcomes |
5 |
|
cancer site-standardized relative survival |
5 |
|
diffusion-weighted imaging |
5 |
|
global health |
5 |
|
head and neck cancer |
5 |
|
health economics |
5 |
|
hepatitis b virus |
5 |
|
imbalanced datasets |
5 |
|
intravoxel incoherent motion |
5 |
|
lymph node metastasis |
5 |
|
machine learning |
5 |
|
magnetic resonance imaging |
5 |
|
myelofibrosis |
5 |
|
neutropenia |
5 |
|
next-generation sequencing |
5 |
|
pediatric |
5 |
|
primary |
5 |
|
prognosis |
5 |
|
re-sampling techniques |
5 |
|
secondary |
5 |
|
surveillance |
5 |
|
vaccination |
5 |
|
acute myeloid leukemia |
4 |
|
adult |
4 |
|
clinical trial |
4 |
|
clofarabine |
4 |
|
cytarabine |
4 |
|
data mining |
4 |
|
depression |
4 |
|
dimensionality reduction |
4 |
|
essential thrombocythemia |
4 |
|
hydroxyurea |
4 |
|
longitudinal study |
4 |
|
mitoxantrone |
4 |
|
myeloproliferative neoplasms |
4 |
|
polycythemia vera |
4 |
|
primary myelofibrosis |
4 |
|
protest |
4 |
|
psoriasis |
4 |
|
sample size |
4 |
|
social media |
4 |
|
social movement |
4 |
|
social psychiatry |
4 |
|
acquired immune deficiency syndrome |
3 |
|
adults |
3 |
|
cancers |
3 |
|
carbohydrates |
3 |
|
cd-risc2 |
3 |
|
china |
3 |
|
chinese |
3 |
|
classification |
3 |
|
cobas |
3 |
|
community |
3 |
|
competing risk analysis |
3 |
|
condom |
3 |
|
condom use |
3 |
|
connor–davidson resilience scale |
3 |
|
disparity |
3 |
|
enterobacteriaceae |
3 |
|
epidemiology |
3 |
|
fiber |
3 |
|
fruits |
3 |
|
gene expression |
3 |
|
heterosexuality |
3 |
|
high-dimensional data |
3 |
|
hiv/aids risks |
3 |
|
hpv test |
3 |
|
human immunodeficiency virus infection |
3 |
|
infection |
3 |
|
men who have sex with men in china |
3 |
|
mendelian randomization |
3 |
|
meta‐analysis |
3 |
|
neutropenic fever |
3 |
|
onclarity |
3 |
|
p-value |
3 |
|
partially overlapping samples |
3 |
|
partnership type |
3 |
|
pathway analysis |
3 |
|
primary screening |
3 |
|
reporting guideline |
3 |
|
reporting quality |
3 |
|
resilience |
3 |
|
second primary cancer |
3 |
|
seer |
3 |
|
statistics |
3 |
|
systematic review |
3 |
|
threshold |
3 |
|
trial design |
3 |
|
vegetables |
3 |
|
whole grains |
3 |
|
advanced cancer |
2 |
|
bevacizumab |
2 |
|
bias-correction |
2 |
|
biomarker |
2 |
|
block-diagonal |
2 |
|
capecitabine |
2 |
|
cis‐eqtl mapping |
2 |
|
clinical trials |
2 |
|
combined modality therapy |
2 |
|
cp: cancer |
2 |
|
endocrine resistance |
2 |
|
epidermal growth factor receptor mutation |
2 |
|
estrogen receptor |
2 |
|
everolimus |
2 |
|
gene-environment interaction |
2 |
|
least‐squares kernel machine |
2 |
|
linear discriminant analysis |
2 |
|
luminal breast cancer |
2 |
|
lung adenocarcinoma |
2 |
|
lung cancer |
2 |
|
mesothelioma |
2 |
|
microarray |
2 |
|
microbial diversity |
2 |
|
multiple variants |
2 |
|
never-smokers |
2 |
|
non-small cell lung cancer |
2 |
|
oxaliplatin |
2 |
|
penalized |
2 |
|
phase i |
2 |
|
predictive models |
2 |
|
prognostic models |
2 |
|
protein degradation |
2 |
|
radio frequency |
2 |
|
radiotherapy |
2 |
|
single nucleotide polymorphisms |
2 |
|
skin microbiome |
2 |
|
skin status |
2 |
|
sociology |
2 |
|
survival |
2 |
|
vegetation |
2 |
|
adaptive design |
1 |
|
adverse events |
1 |
|
adverse events related to age |
1 |
|
african americans |
1 |
|
angiogenesis |
1 |
|
animals |
1 |
|
antiangiogenic therapy |
1 |
|
balance of covariates distribution |
1 |
|
bayesian network |
1 |
|
big data |
1 |
|
biomarkers |
1 |
|
blood |
1 |
|
box’s p-value |
1 |
|
breast cancer |
1 |
|
calgb |
1 |
|
cancer |
1 |
|
case-control studies |
1 |
|
causal inference |
1 |
|
cells, cultured |
1 |
|
cetuximab |
1 |
|
checklist |
1 |
|
chemoradiotherapy |
1 |
|
chemotherapy |
1 |
|
chemotherapy-induced peripheral neuropathy |
1 |
|
clinical outcome prediction |
1 |
|
clinical trial design |
1 |
|
clustering algorithm |
1 |
|
collaboration |
1 |
|
colon adenocarcinoma |
1 |
|
colorectal cancer |
1 |
|
commercialization |
1 |
|
cooperative groups |
1 |
|
cross-sectional study |
1 |
|
cross-validation |
1 |
|
dasatinib |
1 |
|
diabetes |
1 |
|
diagonal hotelling's test |
1 |
|
difference-in-differences |
1 |
|
digital healthcare technology |
1 |
|
discriminant analysis |
1 |
|
dna methylation |
1 |
|
dosage-escalated radiotherapy |
1 |
|
dose finding |
1 |
|
doses |
1 |
|
double-robustness |
1 |
|
duloxetine |
1 |
|
endoglin |
1 |
|
eortc |
1 |
|
epigenetics |
1 |
|
estimand |
1 |
|
extensive-stage small cell lung cancer |
1 |
|
external controls |
1 |
|
external-control |
1 |
|
female |
1 |
|
ganitumab |
1 |
|
gaussian process |
1 |
|
gaussian random process |
1 |
|
gene and pathway-based analysis |
1 |
|
gene expression analysis |
1 |
|
gene expression regulation |
1 |
|
gene selection |
1 |
|
genome-wide scan |
1 |
|
geriatric oncology |
1 |
|
global dietary database |
1 |
|
graph-based semi-supervised learning |
1 |
|
gwas |
1 |
|
health disparities |
1 |
|
hedgehog proteins/*genetics/metabolism |
1 |
|
high dose chemoradiotherapy |
1 |
|
historical control |
1 |
|
historical controls |
1 |
|
human |
1 |
|
humans |
1 |
|
hybrid clinical trials |
1 |
|
hypothyroidism/*etiology/metabolism |
1 |
|
independent validation |
1 |
|
innovation |
1 |
|
integrative analysis |
1 |
|
intetumumab |
1 |
|
invention |
1 |
|
iterative feature elimination |
1 |
|
kaplan–meier curve |
1 |
|
kernel machine |
1 |
|
large p small n |
1 |
|
limited stage |
1 |
|
limited-stage small-cell lung cancer |
1 |
|
liver regeneration/*physiology |
1 |
|
liver/*metabolism/pathology |
1 |
|
locally advanced non-small cell lung cancer |
1 |
|
long-term treatment effect |
1 |
|
longitudinal outcome |
1 |
|
lung toxicity radiation |
1 |
|
machine-learning |
1 |
|
maintenance chemotherapy |
1 |
|
male |
1 |
|
maleneoplasm |
1 |
|
malignant mesothelioma |
1 |
|
marginal likelihood |
1 |
|
marginal treatment effect |
1 |
|
medical research |
1 |
|
meta-analysis |
1 |
|
metastatic colorectal cancer |
1 |
|
mice |
1 |
|
mice, inbred c57bl |
1 |
|
mice, transgenic |
1 |
|
microarray data |
1 |
|
microarrays |
1 |
|
mixed model |
1 |
|
multi-dimensional genomic data |
1 |
|
multiple data sources |
1 |
|
multiple myeloma |
1 |
|
nafld |
1 |
|
natural language processing |
1 |
|
non-alcoholic fatty liver disease/genetics/metabolism/physiopathology |
1 |
|
non-small-cell lung cancer (nsclc) |
1 |
|
null distribution |
1 |
|
nurse scientist |
1 |
|
observational study |
1 |
|
oestrogen receptor |
1 |
|
older patients |
1 |
|
oncology |
1 |
|
open-label extension |
1 |
|
optimal variance estimation |
1 |
|
overall survival |
1 |
|
pain |
1 |
|
panitumumab |
1 |
|
pathology |
1 |
|
pathway |
1 |
|
pathway based analysis |
1 |
|
pathway tests |
1 |
|
performance status |
1 |
|
personalized medicine |
1 |
|
phase i clinical trial |
1 |
|
phase ii |
1 |
|
plasma |
1 |
|
pneumonitis |
1 |
|
power prior |
1 |
|
prebiotics |
1 |
|
prediction validation |
1 |
|
prior-data conflict |
1 |
|
probiotics |
1 |
|
profile likelihood |
1 |
|
prognostic markers |
1 |
|
progression-free survival |
1 |
|
proof of concept |
1 |
|
prophylactic cranial irradiation |
1 |
|
r |
1 |
|
radiation dose |
1 |
|
radiation fields |
1 |
|
random forest |
1 |
|
random forests |
1 |
|
random pathway effects |
1 |
|
rats |
1 |
|
rats, sprague-dawley |
1 |
|
real world data |
1 |
|
real-world data |
1 |
|
refractory colorectal cancer |
1 |
|
regularization |
1 |
|
relevance vector machine |
1 |
|
remote data acquisition |
1 |
|
respiratory tract infections |
1 |
|
restricted maximum likelihood |
1 |
|
risk factors |
1 |
|
romidepsin |
1 |
|
sas macro |
1 |
|
score selection |
1 |
|
score test |
1 |
|
seamless design |
1 |
|
semi-definite programming (sdp)-support vector machine |
1 |
|
serous cystadenocarcinoma |
1 |
|
shrinkage |
1 |
|
signal transduction/genetics |
1 |
|
single-nucleotide polymorphisms |
1 |
|
small cell lung cancer |
1 |
|
small-cell lung cancer |
1 |
|
sorafenib |
1 |
|
src |
1 |
|
src kinase |
1 |
|
statistical analysis plan |
1 |
|
stromal cells/*metabolism/pathology |
1 |
|
study designs |
1 |
|
subsets of covariates |
1 |
|
sunitinib |
1 |
|
surrogate endpoint |
1 |
|
survival analysis |
1 |
|
synbiotics |
1 |
|
synthetic control |
1 |
|
thoracic radiation therapy |
1 |
|
thyroid hormones/metabolism |
1 |
|
time-series clustering |
1 |
|
topoisomerase inhibitor |
1 |
|
toxicity |
1 |
|
toxicity predictors |
1 |
|
translational science |
1 |
|
trc105 |
1 |
|
treatment crossover |
1 |
|
treatment planning |
1 |
|
trend |
1 |
|
tumor classification |
1 |
|
tyrosine kinase inhibitor |
1 |
|
unknown link |
1 |
|
utility |
1 |
|
vascular endothelial growth factor |
1 |
|
wound healing/physiology |
1 |
